# A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy

> **NCT06730932** · PHASE2 · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy

## Interventions

- **DRUG:** JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)

## Key facts

- **NCT ID:** NCT06730932
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730932, "A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06730932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*